Pfizer (PFE) discontinues Beqvez hemophilia B therapy developed with Roche (RHHBY) due to low demand, shifting focus to an ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...

You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Verizon ...

Refugees tend to work hard, are loyal to their employers and often are more willing to relocate than other hires because they ...

Get insights into the standout commercials from Super Bowl LIX that captivated audiences and hit all the right notes.

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...

BridgeBio’s ATTR cardiomyopathy drug, Attruby, achieved promising sales numbers in the weeks after its FDA approval.